Concr
Biotechnology · London, England, United Kingdom · Founded 2018About
Identifying the appropriate treatment for each patient means biomarkers that measure the disease and therapeutic response with high sensitivity and specificity. Concr's technology develops accurate biomarkers that allow safer and more effective cancer treatments to be selected for the right patient at the right time. Concr's astrophysics-derived software is based on proven technology and has high predictive accuracy from minimal patient data. It combines existing and novel disparate datasets and integrates diagnostics across the development pipeline. The platform explicitly calculates added patient outcome and financial value to the system to measure each biomarker’s impact. Current partnerships include Roche and Cancer Research UK.
Company details may include data from People Data Labs, licensed CC BY 4.0.